… inhibitor as a third-line therapy for NSCLC. The PFS of third-line or further anlotinib in the
present … Head-to-head comparisons of anlotinib and chemotherapy as third-line treatment are …

… treatment and the targeted treatment, according … treatments, Chinese patients seldom have
effective drugs to choose from in third-line treatment for further improving their overall survival …

… treatment strategy for the third-line and above treatment of … to investigate the effects of
anlotinib in patients with NSCLC. … progression-free survival (PFS) of these lung cancer patients …

… efficacy and prolong the overall survival (3). In the first-line … The therapeutic effect reached
PR and PFS was more than 7 … mutation patients also showed good response to anlotinib (27). …

… point was progression-free survival (PFS) of the intent-to-treat … control rate (DCR), and
overall survival (OS). The ORR … the anlotinib group was attributable to the treatment effect of …

… ), progression-free survival (PFS), overall survival (… effects, etc. If more than ten articles were
included, a meta-regression analysis was performed to further explore the potential effects of …

… of anlotinib as a third-line and subsequent treatment for … Overall survival (OS) was significantly
longer with anlotinib than … in SCLC patients and did not show favourable effects, although …

… The primary endpoint was overall survival (OS). … anlotinib improved survival in ACC patients
treated with at least two lines of chemotherapy or a TKI. SCC patients who received anlotinib …

… patients who received anlotinib monotherapy as third-line or later-line … influence overall
survival, we observed that 15% of patients (… Treatment-related adverse effects were tolerable and …

… effects; and then, anlotinib plus S-1 treatment was continued. … Progression-free survival
(PFS) was defined as the time from … 23 patients received anlotinib plus S-1 as third-line therapy …